TABLE OF CONTENTS

CLINICAL SUPPORT SYSTEMS FOR DRUG-DRUG INTERACTIONS: IMPLEMENTING EFFECTIVE SYSTEMS, LIMITING MALPRACTICE LIABILITY

FOREWORD: DRUG-DRUG INTERACTION WARNINGS AS TECHNOLOGICAL IATROGENESIS ......................... Nicolas P. Terry 251

ARTICLES

TOO MANY ALERTS, TOO MUCH LIABILITY: SORTING THROUGH THE MALPRACTICE IMPLICATIONS OF DRUG-DRUG INTERACTION CLINICAL DECISION SUPPORT ....................... M. Susan Ridgely Michael D. Greenberg 257

DRUG-DRUG INTERACTION ALERTS: EMPHASIZING THE EVIDENCE ........................ Sharona Hoffman Andy Podgurski 297

THE MARGINAL UTILITY OF MARGINAL GUIDANCE: COMMENTARY ON TOO MANY ALERTS, TOO MUCH LIABILITY: SORTING THROUGH THE MALPRACTICE IMPLICATIONS OF DRUG-DRUG INTERACTION CLINICAL DECISION SUPPORT BY M. SUSAN RIDGELY AND MICHAEL D. GREENBERG ....................................................... Ross Koppel 311
CLINICAL DECISION SUPPORT
AND THE LAW: THE BIG PICTURE......................... David W. Bates 319

ADDRESSING LIABILITY AND
CLINICAL DECISION SUPPORT:
A FEDERAL GOVERNMENT ROLE ..............................Jodi G. Daniel 325

ON OPTIMIZING DDI ALERTS
AND LIABILITY UNDER CDS:
THE AUTHORS RESPOND.....................................Michael D. Greenberg
M. Susan Ridgely 335

STUDENT COMMENT

TO THE FRONT OF THE LINE:
SPURRING BIOTECH
COLLABORATION THROUGH
PATENT FAST-TRACK
EXAMINATION VOUCHERS.................................Scott E. Yackey 341